Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Related Keywords

Daniellem Brander , ,Duke Health ,Duke Cancer Institute ,Hematologic Malignancies ,Cellular Therapy ,International Workshop On Cll ,Onclive Tv ,Conference ,